Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

“The Exact Sciences’ team is helping eradicate cancer while strengthening our platform and growing our business efficiently,” said Kevin Conroy, CEO of Exact Sciences. “During the third quarter, we ...

Exact Sciences Q3 EPS loss of $0.21 fell short of analyst expectations. 2024 revenue guidance lowered amid screening segment ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on EXAS stock, giving a Buy rating yesterday. Puneet Souda’s ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Thanks, operator. Thank you for joining us for Exact Sciences' third-quarter 2024 conference call. On the call today are ...

CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential. Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer ...

You may begin. Thanks, Operator. Thank you for joining us for Exact Sciences third quarter 2024 conference call. On the call today are Kevin Conroy, the company’s Chairman and CEO; and Aaron ...